Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection

Table 1 Predicted peptide candidates used for HAdV-specific T-cell screening in healthy donors

HLA class I restriction	Sequence [aa]	Abbreviation	HAdV species: type [cross-reactivity]	Responders [EliSpot]	T-cell response [reference]
HLA-A*01:01	TDLGQNLLY	A01Hexon_TDLG	C: 1, 2, 5	13/18	High [13, 20, 21]
HLA-A*01:01	TNDQSFNDY	A01Hexon_TNDQ	A: 31, B: 3, C: 1, 2, 5	2/12	No [21]
HLA-A*01:01	QNDPTVVMY	A01Hexon_QNDP	A: 31	0/8	NA
HLA-A*02:01	TLLYVLFEV	A02Hexon _TLLY	A: 31, C:1, 2, 5	28/41	High [13, 22, 23]
HLA-A*02:01	TLAVGDNRV	A02Hexon_TLAV	A: 31, B: 3, C: 1, 2, 5	0/5	No [13]
HLA-B*08:01	GLRYRSMLL	B08Hexon_GLRY	A: 31, B: 3, C: 1, 2, 5	0/5	Minimal [20]
HLA-B*08:01	DLQDRNTEL	B08Hexon _DLQD	A: 31, B: 3, C: 1, 2, 5	6/27	NA
HLA-A*01:01	STDVASLNY	A01Penton _STDV	C: 1, 2, 5	25/38	NA
HLA-A*01:01	SNDSTFTQY	A01Penton_SNDS	C: 1, 2, 5	0/8	NA
HLA-A*01:01	SSDIASLNY	A01Penton_SSDI	A: 31	0/5	NA
HLA-A*01:01	LTDHGTLPL	A01Penton_LTDH	A: 31, B: 3, C: 1, 2, 5	0/5	NA
HLA-A*02:01	ILHTNMPNV	A02Penton _ILHT	A: 31, C: 1, 2, 5	7/28	NA
HLA-A*02:01	ALGIVSPRV	A02Penton_ALGI	A: 31, C: 1, 2, 5	0/6	NA
HLA-A*02:01	GNIPALLDV	A02Penton_GNIP	A: 31, B: 3, C: 1, 2, 5	0/6	NA
HLA-A*03:01	VLESDIGVK	A03Penton_VLES	A: 31, B: 3, C: 1, 2, 5	0/6	NA
HLA-A*03:01	LLPGCGVDF	A03Penton_LLPG	A: 31, B: 3, C: 1, 2, 5	0/6	NA
HLA-B*08:01	NTKYRSWYL	B08Penton_NTKY	A: 31	0/7	NA
HLA-B*08:01	DSKGRSYNL	B08Penton _DSKG	A: 31	9/36	NA
HLA-B*08:01	LTKDKQVEL	B08Penton_LTKD	C: 1, 2	0/5	NA
HLA-B*08:01	DSKKRSYNL	B08Penton _DSKK	C: 1, 2, 5	15/36	NA

Names, sequences and abbreviations of 19 epitope candidates (plus one reference epitope, A01Hexon_TDLG) predicted for frequent HLA class I alleles and clinically relevant HAdV types. The immunogenicity of epitope candidates was evaluated by pre-screening HAdV-specific T-cell responses to the 19 synthesized peptides in healthy donors using IFN-γ EliSpot assay. Seven of 19 peptide candidates induced HAdV-specific T-cell responses, six of which (highlighted in italic) were classified as immunodominant. The following epitope sequences were published elsewhere: A01Hexon_TDLG [13, 20, 21], A01Hexon_TNDQ [21], A02Hexon_TLLY [13, 22, 23], A02Hexon_TLAV [13], and B08Hexon_GLRY [20] (NA not applicable)

ISSN: 1479-5876